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tion and progression of atherosclerosis.GW26-e0984
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OBJECTIVES Calorie restriction (CR) is one of the most effective
nonpharmacological interventions protecting against cardiovascular
disease such as hypertension in the systemic circulation. The aim of
this study is to investigate whether CR could attenuate pulmonary
arterial hypertension (PAH).
METHODS The PAH model was developed by subjecting the rats to
a single subcutaneous injection of monocrotaline (MCT, 60 mg/kg).
The CR rats received 90% of the average caloric intake of ad libi-
tum-fed animals before MCT injection for 2 weeks, followed by 65%
of the caloric intake of the control rats after MCT injection for 3
weeks.
RESULTS Five weeks of short-term CR reduced gain in body weight
signiﬁcantly, while it did not alter tibia length compared with
controls, indicating that CR did not affect growth. CR lowered mean
pulmonary arterial pressure (mPAP: 21.12.1 vs. 30.42.0 of MCT
control, n¼6, P<0.05) and reduced vascular remodeling (cross-
sectional medial wall area/total arterial cross-sectional area:
74.34.2 vs. 90.13.9 of MCT control, n¼6, P<0.05) and right
ventricular hypertrophy (right ventricle /(left ventricleþseptum):
0.330.03 vs. 0.440.02 of MCT control, n¼6, P<0.01) in PAH rats
at 3 weeks after MCT injection. Meanwhile, CR attenuated endo-
thelial dysfunction as evidenced by increased relaxation in response
to ACh. The beneﬁcial effects of CR were associated with restored
SIRT1 expression and eNOS phosphorylation and reduced eNOS
acetylation in pulmonary arteries of PAH rats. To further clarify the
role of SIRT1 in the protective effects of CR, adenoviral vectors for
overexpression of SIRT1 (Ad. SIRT1) was administered intra-
tracheally at 1 d before MCT injection. Ad. SIRT1 exhibited similar
preventive effects on mPAP (24.12.8 vs. 33.42.2 of MCTþ Ad.
GFP, n¼6, P<0.05) and endothelial function, and increased eNOS
phosphorylation and reduced eNOS acetylation in the absence of
CR. Moreover, SIRT1 overexpression attenuated the increase in
mPAP in hypoxic pulmonary hypertension (HPH) animals after 2
weeks of hypoxia (20.11.8 vs. 28.42.1 of HPHþAd. GFP, n¼6,
P<0.05).
CONCLUSIONS The present data demonstrate that CR may serve as an
effective treatment of PAH, and targeting the SIRT1/eNOS pathway
may improve treatment of PAH.GW26-e1238
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OBJECTIVES This aim of this study was to measure the mRNA and
protein expression levels of NCX1. Moreover, we plan to observe the
difference of NCX1 level between the patients with chronic atrial
ﬁbrillation and the patients with sinus rhythm.
METHODS The protocol of this study was approved by Ethics Re-
view Board of Luzhou Medical College. Written letters of consent
were obtained from all members, and all of the procedures were
done in accordance with the Declaration of Helsinki and relevant
policies in China. Specimens of right atrial appendage were ob-
tained from patients who accepted cardopulmonary bypass. There
were no statistical differences in age and gender. NCX1 mRNA
level was obtained from 14 patients with sinus rhythm (SR group)
and 25 patients with chronic atrial ﬁbrillation (AF group).The protein extractions were detected by western blotting. NCX1
protein level was obtained from 24 patients with sinus rhythm
(SR group) and 28 patients with chronic atrial ﬁbrillation (AF
group). The expression of mRNA were detected by quantitative
real-time PCR. The data was analyzed with 2-DDCT method. The
statistical analysis was done using independent-samples T test by
SPSS 17.0.
RESULTS The mRNA expression levels of NCX1 were increased in
AF group compared with SR group. The expression of NCX1 in
chronic atrial ﬁbrillation patients was 48.14% higher than that of
sinus rhythm patients (P＜0.05). The relative expression of NCX1
protein in AF group was 1.390.52, while it was 0.760.22 in SR
group (P＜0.05).
CONCLUSIONS The mRNA and protein expression level of NCX1
was signiﬁcantly up-regulated in patients with chronic atrial ﬁbril-
lation. It may demonstrate that NCX1 are involved electrical
remodeling of chronic atrial ﬁbrillation. These ﬁnding provide a
new insight into mechanisms of chronic atrial ﬁbrillation. Mean-
while, NCX1 may become a new treatment target of chronic atrial
ﬁbrillation.GW26-e1369
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in Chinese pedigrees with familial hypertrophic cardiomyopathy
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OBJECTIVES To screen MYH7 gene mutation in Chinese pedigrees
with familial hypertrophic cardiomyopathy (FHCM) and to analyse the
correlation between genotype and phenotype.
METHODS Specimens of peripheral blood were collected from
thirteen probands of Chinese pedigrees with hypertrophic cardio-
myopathy (HCM) and 100 normal control subjects. The genome
DNA was extracted. The 3～27 exons in the functional region of
the MYH7 gene were ampliﬁed with PCR and the products were
sequenced. The results were analyzed and mutation sites were
determined. Further genetic testing and clinical investigation were
done on the other members of the families with the positive re-
sults. The correlation between genotype and phenotype was
analyzed.
RESULTS Arg1114Cys and Glu1142Lys mutations were identiﬁed in
exon 26 in two pedigrees, and were found cosegregate with the
disease. No similar mutations were identiﬁed in controls. The two
mutations were found for the ﬁrst time at home and abroad and the
two pedigrees had different clinical phenotype. Six members carried
the Arg1114Cys mutation in the pedigree, and three of them were
diagnosed as HCM, all female, were the proband(59 years old), the
proband’s mother(82 years old) and second sister(56 years old),ECG
all showed ST-T abnormal, echocardiography all demonstrated the
signiﬁcantly thickness of ventricular septal, the max thickness varied
in 16-20mm,one with left ventricular outﬂow tract light degree
obstruction, the other two with no obstruction in left ventricular
outﬂow tract. The proband’s third sister (50 years old) and her son,
daughter (17, 28 years old) were all not HCM patients but carried the
mutation, ECG and echocardiography were normal. In the pedigree
carried the Glu1142Lys mutation, 2 members were diagnosed as
HCM,1 carried the mutation(the proband), male, 32 years old, ECG
shows ST-T abnormal, echocardiography demonstrated the max
thickness of ventricular septal was 32mm,left ventricular outﬂow
tract with middle degree obstruction. Another HCM patient was the
proband’s father, dead suddenly in 2012. The proband’s daughter
and sister didn’t found mutation, ECG and echocardiography were
all normal.
CONCLUSIONS Few mutations occurred in the rod domain of MYH7,
about 20%. The two mutations found in the research were both in
exon 26 in the rod domain. The pedigree carried Arg1114Cys mutation
had a low rate of penetrance, a light degree of myocardial hypertro-
phy, mild symptoms, a slow progress and good survival prognosis.
The pedigree carried Glu1142Lys mutation had a severe degree of
myocardial hypertrophy, high risk of sudden cardiac death and an
unfavorable prognosis.
